SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    M. Shah, A. Shankar, I. Gee, K. Nash, M. Hoare, P. Gibbs, S. Davies, G. J. M. Alexander, A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients, Alimentary Pharmacology & Therapeutics, 2015, 41, 4
  2. 2
    Zhuo-Yi Wang, Lei Geng, Shu-Sen Zheng, Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation, Hepatobiliary & Pancreatic Diseases International, 2015, 14, 2, 145

    CrossRef

  3. 3
    P. Fitzmorris, M. Shoreibah, B. S. Anand, A. K. Singal, Management of hepatocellular carcinoma, Journal of Cancer Research and Clinical Oncology, 2015, 141, 5, 861

    CrossRef

  4. 4
    Christophe Duvoux, Christian Toso, mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?, Transplantation Reviews, 2015, 29, 3, 168

    CrossRef

  5. 5
    Itxarone Bilbao, Magdalena Salcedo, Miguel Angel Gómez, Carlos Jimenez, Javier Castroagudín, Joan Fabregat, Carolina Almohalla, Ignacio Herrero, Valentín Cuervas-Mons, Alejandra Otero, Angel Rubín, Manuel Miras, Juan Rodrigo, Trinidad Serrano, Gonzalo Crespo, Manuel De la Mata, Javier Bustamante, M. Luisa Gonzalez-Dieguez, Antonia Moreno, Isidoro Narvaez, Magda Guilera, Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain, Liver Transplantation, 2015, 21, 8
  6. 6
    Andrea Mancuso, Alessandra Mazzola, Giuseppe Cabibbo, Giovanni Perricone, Marco Enea, Antonio Galvano, Claudio Zavaglia, Luca Belli, Calogero Cammà, Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis, Digestive and Liver Disease, 2015, 47, 4, 324

    CrossRef

  7. 7
    Greg J. McKenna, Göran B.G. Klintmalm, Transplantation of the Liver, 2015,

    CrossRef

  8. 8
    Johnny C. Hong, Ronald W. Busuttil, Transplantation of the Liver, 2015,

    CrossRef

  9. 9
    Michael A. Zimmerman, Nicholas Onaca, Göran B.G. Klintmalm, Transplantation of the Liver, 2015,

    CrossRef

  10. 10
    Vanessa J. Lavallard, Philippe Gual, Autophagy and Non-Alcoholic Fatty Liver Disease, BioMed Research International, 2014, 2014, 1

    CrossRef

  11. 11
    Εvangelos Cholongitas, Ioannis Goulis, Eleni Theocharidou, Nikolaos Antoniadis, Ioannis Fouzas, Dimitrios Giakoustidis, George Imvrios, Olga Giouleme, Vasilios Papanikolaou, Evangelos Akriviadis, Themistoklis Vasiliadis, Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience, Hepatology International, 2014, 8, 1, 137

    CrossRef

  12. 12
    Ju-Yeun Lee, Yul Hee Kim, Nam-Joon Yi, Hyang Sook Kim, Hye Suk Lee, Byung Koo Lee, Hyeyoung Kim, Young Rok Choi, Geun Hong, Kwang-Woong Lee, Kyung-Suk Suh, Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation, Clinical and Molecular Hepatology, 2014, 20, 2, 192

    CrossRef

  13. 13
    Manuel Rodríguez-Perálvarez, Manuel De la Mata, Andrew K. Burroughs, Liver transplantation, Current Opinion in Organ Transplantation, 2014, 19, 3, 253

    CrossRef

  14. 14
    A. Kornberg, Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome, ISRN Hepatology, 2014, 2014, 1

    CrossRef

  15. 15
    Haniee Chung, William C Chapman, Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future?, Hepatic Oncology, 2014, 1, 3, 309

    CrossRef

  16. 16
    Evangelos Cholongitas, Chrysanthi Mamou, Kryssia I. Rodríguez-Castro, Patrizia Burra, Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review, Transplant International, 2014, 27, 10
  17. 17
    C.M. Sommer, U. Stampfl, H.U. Kauczor, P.L. Pereira, Nationale S3-Leitlinie hepatozelluläres Karzinom, Der Radiologe, 2014, 54, 7, 642

    CrossRef

  18. 18
    Wenjuan Huang, Fengrong Zhao, Ying Huang, Xia Li, Sufei Zhu, Qin Hu, Weixian Chen, Fengrong Zhao, Ying Huang, Xia Li, Rapamycin Enhances HBV Production by Inducing Cellular Autophagy, Hepatitis Monthly, 2014, 14, 10

    CrossRef

  19. 19
    Kan Chen, Kwan Man, Herold J. Metselaar, Harry L. A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan, Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation, Liver Transplantation, 2014, 20, 3
  20. 20
    Sung-Hwa Kang, Shin Hwang, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Gil-Chun Park, Bo-Hyun Jung, Young-In Yoon, Sung-Gyu Lee, Tailored long-term immunosuppressive regimen for adult liver transplant recipients with hepatocellular carcinoma, Korean Journal of Hepato-Biliary-Pancreatic Surgery, 2014, 18, 2, 48

    CrossRef

  21. 21
    Young-Nam Roh, Choon Hyuck David Kwon, Sanghyun Song, Milljae Shin, Jong Man Kim, Sungjoo Kim, Jae-Won Joh, Suk-Koo Lee, The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation, Clinical Transplantation, 2014, 28, 1
  22. 22
    Goran B. Klintmalm, Björn Nashan, The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence, Journal of Transplantation, 2014, 2014, 1

    CrossRef

  23. 23
    Toshiyasu Kawahara, Christian Toso, Keisuke Yamaguchi, Sonia Cader, Donna N. Douglas, Mahra Nourbakhsh, Jamie T. Lewis, Thomas A. Churchill, Hideo Yagita, Norman M. Kneteman, Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma, Liver International, 2013, 33, 9
  24. 24
    M. Fujiki, F. Aucejo, R. Kim, Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?, Clinical Transplantation, 2013, 27, 2
  25. 25
    Claudio Zavaglia, Aldo Airoldi, Andrea Mancuso, Marcello Vangeli, Raffaella Viganò, Gabriella Cordone, Maria Gentiluomo, Luca Saverio Belli, Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation, European Journal of Gastroenterology & Hepatology, 2013, 25, 2, 180

    CrossRef

  26. 26
    Lewis Teperman, Dilip Moonka, Anthony Sebastian, Linda Sher, Paul Marotta, Christopher Marsh, Baburao Koneru, John Goss, Dennis Preston, John P. Roberts, Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare-the-Nephron Trial, Liver Transplantation, 2013, 19, 7
  27. 27
    Vincent Donckier, Ligia Craciun, Patrick Miqueu, Roberto Ivan Troisi, Valerio Lucidi, Xavier Rogiers, Nathalie Boon, Delphine Degré, Alexis Buggenhout, Christophe Moreno, Thierry Gustot, Maurizio Sainz-Barriga, Nadine Bourgeois, Isabelle Colle, Hans Van Vlierberghe, Mohammed Amrani, Myriam Remmelink, Arnaud Lemmers, Dave L. Roelen, Frans H. Claas, Petra Reinke, Birgit Sawitzki, Hans Dieter Volk, Alain Le Moine, Bernard de Hemptinne, Michel Goldman, Expansion of Memory-Type CD8+ T Cells Correlates With the Failure of Early Immunosuppression Withdrawal After Cadaver Liver Transplantation Using High-Dose ATG Induction and Rapamycin, Transplantation Journal, 2013, 96, 3, 306

    CrossRef

  28. 28
    Christian Toso, Sonia Cader, Ariane Mentha-Dugerdil, Glenda Meeberg, Pietro Majno, Isabelle Morard, Emiliano Giostra, Thierry Berney, Philippe Morel, Gilles Mentha, Norman M. Kneteman, Factors predicting survival after post-transplant hepatocellular carcinoma recurrence, Journal of Hepato-Biliary-Pancreatic Sciences, 2013, 20, 3
  29. You have free access to this content29
    Neil Mehta, Ryutaro Hirose, Immunosuppression: Conventions and controversies, Clinical Liver Disease, 2013, 2, 4
  30. 30
    Christian Toso, Gilles Mentha, Pietro Majno, Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence, Journal of Hepatology, 2013, 59, 1, 3

    CrossRef

  31. 31
    V. Müller, T. Förtsch, M. Gündel, R.S. Croner, M. Langheinrich, S. Yedibela, C. Lohmüller, M. Küffner, W. Hohenberger, A. Perrakis, Long-Term Outcome of Liver Transplantation as Treatment Modality in Patients With Hepatocellular Carcinoma in Cirrhosis: A Single-Center Experience, Transplantation Proceedings, 2013, 45, 5, 1957

    CrossRef

  32. 32
    Emad H. Asham, Ahmed Kaseb, R. Mark Ghobrial, Management of Hepatocellular Carcinoma, Surgical Clinics of North America, 2013, 93, 6, 1423

    CrossRef

  33. You have free access to this content33
    K. V. Menon, A. R. Hakeem, N. D. Heaton, Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, 2013, 37, 4
  34. 34
    Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma, Digestive and Liver Disease, 2013, 45, 9, 712

    CrossRef

  35. 35
    Manuel Rodríguez-Perálvarez, Emmanuel Tsochatzis, María Carmen Naveas, Giulia Pieri, Carmen García-Caparrós, James O’Beirne, Antonio Poyato-González, Gustavo Ferrín-Sánchez, Jose Luis Montero-Álvarez, David Patch, Douglas Thorburn, Javier Briceño, Manuel De la Mata, Andrew Kenneth Burroughs, Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma, Journal of Hepatology, 2013, 59, 6, 1193

    CrossRef

  36. 36
    Jan Pfeiffenberger, Ronald Koschny, Katrin Hoffmann, Arianeb Mehrabi, Anne Schmitz, Boris Radeleff, Wolfgang Stremmel, Peter Schemmer, Tom M. Ganten, Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation, Langenbeck's Archives of Surgery, 2013, 398, 8, 1123

    CrossRef

  37. 37
    Min-Soo Kim, Jeong-Soo Kim, Wonkyung Cho, Kwang-Ho Cha, Hee-Jun Park, Junsung Park, Sung-Joo Hwang, Supersaturatable formulations for the enhanced oral absorption of sirolimus, International Journal of Pharmaceutics, 2013, 445, 1-2, 108

    CrossRef

  38. 38
    YoungRok Choi, Kwang-Woong Lee, The Management of HCV Recurrence after Liver Transplantation, The Journal of the Korean Society for Transplantation, 2013, 27, 2, 37

    CrossRef

  39. 39
    Kenya Yamanaka, Marius Petrulionis, Shibo Lin, Chao Gao, Uwe Galli, Susanne Richter, Susanne Winkler, Philipp Houben, Daniel Schultze, Etsuro Hatano, Peter Schemmer, Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis, Cancer Medicine, 2013, 2, 6
  40. 40
    Angel Rubín, Marina Berenguer, Trasplante hepático: inmunosupresión personalizada en pacientes con hepatitis C y carcinoma hepatocelular, Gastroenterología y Hepatología, 2013, 36, 1, 48

    CrossRef

  41. 41
    Adrian Reuben, Drug-induced Liver Disease, 2013,

    CrossRef

  42. 42
    J.M. Álamo, C. Bernal, L.M. Marín, G. Suárez, J. Serrano, L. Barrera, J.M. Sousa, F.J. Padillo, M.A. Gómez-Bravo, Antitumor Efficacy of Mammalian Target of Rapamycin Inhibitor Therapy in Liver Transplant Recipients With Oncological Disease: A Case-Control Study, Transplantation Proceedings, 2012, 44, 7, 2089

    CrossRef

  43. 43
    P. Puneet, M. T. P. R. Perera, Darius F. Mirza, Current opinion on the role of resection and liver transplantation for hepatocellular cancer, Indian Journal of Gastroenterology, 2012, 31, 3, 89

    CrossRef

  44. 44
    Emmanuel Melloul, Mickael Lesurtel, Brian I. Carr, Pierre-Alain Clavien, Developments in Liver Transplantation for Hepatocellular Carcinoma, Seminars in Oncology, 2012, 39, 4, 510

    CrossRef

  45. 45
    P. De Simone, F. Nevens, L. De Carlis, H. J. Metselaar, S. Beckebaum, F. Saliba, S. Jonas, D. Sudan, J. Fung, L. Fischer, C. Duvoux, K. D. Chavin, B. Koneru, M. A. Huang, W. C. Chapman, D. Foltys, S. Witte, H. Jiang, J. M. Hexham, G. Junge, Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial, American Journal of Transplantation, 2012, 12, 11
  46. 46
    Katharina Staufer, Lutz Fischer, Barbara Seegers, Eik Vettorazzi, Bjoern Nashan, Martina Sterneck, High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation, Transplant International, 2012, 25, 11
  47. 47
    Ali Zarrinpar, Ronald W Busuttil, Immunomodulating options for liver transplant patients, Expert Review of Clinical Immunology, 2012, 8, 6, 565

    CrossRef

  48. 48
    Dimitrios N. Samonakis, Giacomo Germani, Andrew K. Burroughs, Immunosuppression and HCV recurrence after liver transplantation, Journal of Hepatology, 2012, 56, 4, 973

    CrossRef

  49. 49
    A. Morcos, S. Nair, M. P. Keane, N. G. McElvaney, P. A. McCormick, Interstitial pneumonitis is a frequent complication in liver transplant recipients treated with sirolimus, Irish Journal of Medical Science, 2012, 181, 2, 231

    CrossRef

  50. 50
    Rahul Kakodkar, A. S. Soin, Liver Transplantation for HCC: A Review, Indian Journal of Surgery, 2012, 74, 1, 100

    CrossRef

  51. 51
    Josep M. Campistol, Valentín Cuervas-Mons, Nicolás Manito, Luis Almenar, Manuel Arias, Fernando Casafont, Domingo del Castillo, María G. Crespo-Leiro, Juan F. Delgado, J. Ignacio Herrero, Paloma Jara, José M. Morales, Mercedes Navarro, Federico Oppenheimer, Martín Prieto, Luis A. Pulpón, Antoni Rimola, Antonio Román, Daniel Serón, Piedad Ussetti, New concepts and best practices for management of pre- and post-transplantation cancer, Transplantation Reviews, 2012, 26, 4, 261

    CrossRef

  52. 52
    Abbas Rana, Johnny C. Hong, Orthotopic liver transplantation in combination with neoadjuvant therapy, Current Opinion in Gastroenterology, 2012, 28, 3, 258

    CrossRef

  53. 53
    Alwine Kist, Joris Wakkie, Max Madu, Ruth Versteeg, Judith ten Berge, Andrej Nikolic, Vincent B. Nieuwenhuijs, Robert J. Porte, Robert T.A. Padbury, Greg J. Barritt, Rapamycin Induces Heme Oxygenase-1 in Liver but Inhibits Bile Flow Recovery after Ischemia, Journal of Surgical Research, 2012, 176, 2, 468

    CrossRef

  54. 54
    Pierre-Alain Clavien, Mickael Lesurtel, Patrick MM Bossuyt, Gregory J Gores, Bernard Langer, Arnaud Perrier, Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report, The Lancet Oncology, 2012, 13, 1, e11

    CrossRef

  55. 55
    Sandra E. Fischer, Recurrent and de novo malignancies following liver transplantation, Diagnostic Histopathology, 2012, 18, 7, 290

    CrossRef

  56. 56
    Shin Hwang, Yong-Hee Kim, Dong Kwan Kim, Chul-Soo Ahn, Deog-Bok Moon, Ki-Hun Kim, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Hyeong Ryul Kim, Gil-Chun Park, Jeong-Man Namgoong, Sam-Youl Yoon, Sung-Won Jung, Seung Il Park, Sung-Gyu Lee, Resection of Pulmonary Metastases from Hepatocellular Carcinoma following Liver Transplantation, World Journal of Surgery, 2012, 36, 7, 1592

    CrossRef

  57. 57
    Martin-Walter Welker, Jörg Trojan, Rezidiv des hepatozellulären Karzinoms nach orthotoper Lebertransplantation: Nachsorge und therapeutische Optionen, Viszeralmedizin, 2012, 28, 5, 338

    CrossRef

  58. 58
    Gyula Végső, Dénes Görög, Imre Fehérvári, Balázs Nemes, Attila Doros, Róbert Miklós Langer, László Kóbori, Role of Organ Transplantation in the Treatment of Malignancies – Hepatocellular Carcinoma as the Most Common Tumour Treated with Transplantation, Pathology & Oncology Research, 2012, 18, 1, 1

    CrossRef

  59. 59
    Greg J. McKenna, James F. Trotter, Sirolimus – It doesn’t deserve its bad Rap(a), Journal of Hepatology, 2012, 56, 1, 285

    CrossRef

  60. 60
    C.H.P. Reigada, E.C. de Ataide, F.R. de Araújo, A.P. Ramos, R.S.B. Stucchi, C.A.F. Eescanhoela, I.F.S.F. Boin, Sirolimus as Rescue Therapy After Liver Transplantation, Transplantation Proceedings, 2012, 44, 8, 2434

    CrossRef

  61. 61
    Xiongwei Hu, Chen Lin, Dingxiong Chen, Jing Zhang, Zhihong Liu, Wei Wu, Hongtao Song, Sirolimus solid self-microemulsifying pellets: Formulation development, characterization and bioavailability evaluation, International Journal of Pharmaceutics, 2012, 438, 1-2, 123

    CrossRef

  62. 62
    Wenhua Liang, Dongping Wang, Xiaoting Ling, Andrew Allen Kao, Yuan Kong, Yushu Shang, Zhiyong Guo, Xiaoshun He, Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis, Liver Transplantation, 2012, 18, 1
  63. 63
    Arndt Weinmann, Ina Maria Niederle, Sandra Koch, Maria Hoppe-Lotichius, Michael Heise, Christoph Düber, Marcus Schuchmann, Gerd Otto, Peter Robert Galle, Marcus-Alexander Wörns, Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation, Digestive and Liver Disease, 2012, 44, 5, 432

    CrossRef

  64. 64
    J.I. Herrero, A. España, D. D'Avola, F. Pardo, M. Iñarrairaegui, F. Rotellar, B. Sangro, J. Quiroga, Subsequent Nonmelanoma Skin Cancer after Liver Transplantation, Transplantation Proceedings, 2012, 44, 6, 1568

    CrossRef

  65. 65
    J. R. L. Maggs, A. R. Suddle, V. Aluvihare, M. A. Heneghan, Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, 2012, 35, 10
  66. 66
    Omar Massoud, Russell H. Wiesner, The use of Sirolimus should be restricted in liver transplantation, Journal of Hepatology, 2012, 56, 1, 288

    CrossRef

  67. 67
    Jeffrey Campsen, Michael A. Zimmerman, Susan Mandell, Maria Kaplan, Igal Kam, A Decade of Experience Using mTor Inhibitors in Liver Transplantation, Journal of Transplantation, 2011, 2011, 1

    CrossRef

  68. 68
    Valentina Rosa Bertuzzo, Matteo Cescon, Matteo Ravaioli, Gian Luca Grazi, Giorgio Ercolani, Massimo Del Gaudio, Alessandro Cucchetti, Antonietta DʼErrico-Grigioni, Rita Golfieri, Antonio Daniele Pinna, Analysis of Factors Affecting Recurrence of Hepatocellular Carcinoma After Liver Transplantation With a Special Focus on Inflammation Markers, Transplantation, 2011, 91, 11, 1279

    CrossRef

  69. 69
    J.F. Castroagudín, E. Molina, E. Varo, Calcineurin Inhibitors in Liver Transplantation: To Be or Not to Be, Transplantation Proceedings, 2011, 43, 6, 2220

    CrossRef

  70. 70
    F. Di Benedetto, G. D'Amico, N. De Ruvo, S. Cocchi, R. Montalti, N. Cautero, G.P. Guerrini, R. Ballarin, M. Spaggiari, G. Tarantino, B. Baisi, G. Cappelli, M. Codeluppi, G.E. Gerunda, Combined liver–kidney transplantation in patients infected with human immunodeficiency virus, Transplant Infectious Disease, 2011, 13, 5
  71. 71
    Faouzi Saliba, Sébastien Dharancy, Richard Lorho, Filoména Conti, Sylvie Radenne, Martine Neau-Cransac, Monika Hurtova, Jean Hardwigsen, Yvon Calmus, Jérome Dumortier, Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis, Liver Transplantation, 2011, 17, 8
  72. 72
    T. Casanovas, A. Argudo, M.C. Peña-Cala, Everolimus in Clinical Practice in Long-Term Liver Transplantation: An Observational Study, Transplantation Proceedings, 2011, 43, 6, 2216

    CrossRef

  73. 73
    Daniel Shouval, Focus, Journal of Hepatology, 2011, 55, 2, 243

    CrossRef

  74. 74
    Nuh N. Rahbari, Arianeb Mehrabi, Nathan M. Mollberg, Sascha A. Müller, Moritz Koch, Markus W. Büchler, Jürgen Weitz, Hepatocellular Carcinoma, Annals of Surgery, 2011, 253, 3, 453

    CrossRef

  75. 75
    Yasunobu Matsuda, Takafumi Ichida, Manabu Fukumoto, Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies, Medical Molecular Morphology, 2011, 44, 3, 117

    CrossRef

  76. 76
    Hans J. Schlitt, Andreas A. Schnitzbauer, Hepatocellular carcinoma: Agents and concepts for preventing recurrence after curative treatment, Liver Transplantation, 2011, 17, S3
  77. 77
    Hans J. Schlitt, Françoise Mornex, Abraham Shaked, James F. Trotter, Immunosuppression and hepatocellular carcinoma, Liver Transplantation, 2011, 17, S2
  78. 78
    Andreas A. Schnitzbauer, Hans J. Schlitt, Edward K. Geissler, Influence of Immunosuppressive Drugs on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Gap Between Basic Science and Clinical Evidence, Transplantation, 2011, 91, 11, 1173

    CrossRef

  79. 79
    Christopher Soll, Pierre-Alain Clavien, Inhibition of mammalian target of rapamycin: Two goals with one shot?, Journal of Hepatology, 2011, 54, 1, 182

    CrossRef

  80. 80
    Ali Zarrinpar, Fady Kaldas, Ronald W Busuttil, Liver transplantation for hepatocellular carcinoma: an update, Hepatobiliary & Pancreatic Diseases International, 2011, 10, 3, 234

    CrossRef

  81. 81
    C. Toso, G. Mentha, P. Majno, Liver Transplantation for Hepatocellular Carcinoma: Five Steps to Prevent Recurrence, American Journal of Transplantation, 2011, 11, 10
  82. 82
    Toshiyasu Kawahara, Sonal Asthana, Norman M. Kneteman, m-TOR inhibitors: What role in liver transplantation?, Journal of Hepatology, 2011, 55, 6, 1441

    CrossRef

  83. 83
    Josh Levitsky, Olaf Guckelberger, Meeting Report of the 16th Annual International Congress of the International Liver Transplantation Society, Liver Transplantation, 2011, 17, 1
  84. 84
    Oliver Waidmann, Wolf-Peter Hofmann, Stefan Zeuzem, Joerg Trojan, mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation, Journal of Hepatology, 2011, 54, 2, 396

    CrossRef

  85. 85
    Eleonora Patsenker, Vreni Schneider, Monika Ledermann, Hans Saegesser, Christoph Dorn, Claus Hellerbrand, Felix Stickel, Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis, Journal of Hepatology, 2011, 55, 2, 388

    CrossRef

  86. 86
    Johnny C. Hong, Henrik Petrowsky, Fady M. Kaldas, Douglas G. Farmer, Francisco A. Durazo, Richard S. Finn, Sammy Saab, Steven-Huy Han, Percy Lee, Daniela Markovic, Charles Lassman, Jonathan R. Hiatt, Ronald W. Busuttil, Predictive Index for Tumor Recurrence after Liver Transplantation for Locally Advanced Intrahepatic and Hilar Cholangiocarcinoma, Journal of the American College of Surgeons, 2011, 212, 4, 514

    CrossRef

  87. 87
    Russell H. Wiesner, John J. Fung, Present state of immunosuppressive therapy in liver transplant recipients, Liver Transplantation, 2011, 17, S3
  88. 88
    Corinna La Rosa, Ajit P. Limaye, Aparna Krishnan, Gideon Blumstein, Jeff Longmate, Don J. Diamond, Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients, Transplant International, 2011, 24, 9
  89. 89
    Klára Werling, Role of autophagy in the pathogenesis of liver diseases, Orvosi Hetilap, 2011, 152, 49, 1955

    CrossRef

  90. 90
    Massimiliano Veroux, Tiziano Tallarita, Daniela Corona, Antonino D’Assoro, Carmelina Gurrieri, Pierfrancesco Veroux, Sirolimus in solid organ transplantation: current therapies and new frontiers, Immunotherapy, 2011, 3, 12, 1487

    CrossRef

  91. You have free access to this content91
    G. J. M. Alexander, Sirolimus Is Coming of Age, American Journal of Transplantation, 2011, 11, 11
  92. 92
    J.F. Castroagudín, E. Molina-Pérez, R. Ferreiro-Iglesias, E. Varo-Pérez, Strategies of Immunosuppression for Liver Transplant Recipients With Hepatocellular Carcinoma, Transplantation Proceedings, 2011, 43, 3, 711

    CrossRef

  93. 93
    Shaheed Merani, Pietro Majno, Norman M. Kneteman, Thierry Berney, Philippe Morel, Gilles Mentha, Christian Toso, The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma, Journal of Hepatology, 2011, 55, 4, 814

    CrossRef

  94. 94
    Francesca Ponziani, Veronica Ojetti, Annalisa Tortora, Luca Di Maurizio, Flaminia Purchiaroni, Antonio Gasbarrini, The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma, Expert Opinion on Drug Metabolism & Toxicology, 2011, 7, 12, 1535

    CrossRef

  95. 95
    Dominic Dell-Olio, Deirdre A Kelly, Immunosuppressants: whatʼs new?, Current Opinion in Organ Transplantation, 2010, 15, 5, 594

    CrossRef

  96. 96
    Christopher Soll, Pierre-Alain Clavien, Inhibition of mammalian target of rapamycin: The janus face of immunosuppression?, Hepatology, 2010, 51, 4
  97. 97
    James Neuberger, New developments in immunosuppression, Liver Transplantation, 2010, 16, S2
  98. 98
    M. Schöniger-Hekele, C. Müller, Pilot study: rapamycin in advanced hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, 2010, 32, 6
  99. 99
    D.M. Harnois, Sirolimus-Based Immunosuppression Is Associated with Increased Survival After Liver Transplantation for Hepatocellular Carcinoma, Yearbook of Gastroenterology, 2010, 2010, 243

    CrossRef

  100. You have free access to this content100
    Sherrie Bhoori, Carlo Sposito, Alessandro Germini, Jorgelina Coppa, Vincenzo Mazzaferro, The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis, Transplant International, 2010, 23, 7
  101. 101
    Russell H. Wiesner, Immunosuppression: The Global Picture,
  102. 102
    Timothy M. McCashland, Long-Term Management of the Liver Transplant Patient,
  103. 103
    A.M. James Shapiro, Camillo Ricordi, Long-term Outcomes after Islet Transplantation,
  104. 104
    Natasha Chandok, Kymberly D. S. Watt, Post-Transplant Lymphoproliferative Disorder and other Malignancies after Liver Transplantation,
  105. 105
    Samir Parekh, James R. Spivey, Recurrent Disease after Liver Transplantation,